MedTrace Logo

Self Soft Tissue Therapy for Fibromyalgia Syndrome

NCT02881411 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-14

No results posted yet for this study

Summary

The main aims of this preliminary research are to determine if combined self-soft tissue therapy (SSTT) alongside an established 6 week FMS Coping Skills Programme (FCSP) is a feasible and acceptable treatment approach for FMS. All participants on the six week FCSP will be randomly allocated to a control (FMS Coping Skills Programme) or intervention group (FMS Coping Skills Programme plus SSTT). All participants will be assessed for outcome measurements at the start of the feasibility study, at six weeks and three months after completion.

This feasibility study hypothesis is that the SST approach will be acceptable to FMS patients and that the combined 6 week FCSP (hands off) and SSTT (hands on) will be beneficial. This feasibility study will inform a larger randomized controlled trial (RCT) on this combined treatment approach to FMS.

Conditions

  • Fibromyalgia Syndrome

Interventions

OTHER

Self-soft tissue therapy

Manual therapy for the muscles in the upper or lower limbs.

OTHER

Fibromyalgia coping skills programme

Exercise, education programme

Sponsors & Collaborators

  • Royal United Hospital Bath NHS Trust

    collaborator OTHER

  • University of the West of England

    lead OTHER

Principal Investigators

  • Rob M Grieve, PhD · University of the West of England

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881411 on ClinicalTrials.gov